BPC-157
Body Protection Compound
BPC-157 is a synthetic 15-amino-acid partial sequence derived from a protective protein found in human gastric juice, studied almost entirely in animals for gut and soft-tissue healing.
Regulatory status: Not approved by the FDA or any other regulator as a drug, and the FDA has stated it is excluded from use as a dietary-supplement ingredient. Material sold online is offered for research use only.
Default vial
5 mg
Default mix
2 mL
Reported range
200–500 mcg
Draw (U-100)
10 u
Often split AM/PM for gut protocols, or injected near the site of injury for local repair.
What it is
- A 15-amino-acid partial sequence of a human gastric-juice protective protein, which is why the literature calls it a gastric pentadecapeptide.
- Synthetic and stable in gastric fluid; it does not occur naturally in this exact form.
- Most published studies administer it by intraperitoneal or subcutaneous injection in rodents; some gut studies use oral dosing.
- Published work concentrates on ulcer, tendon, ligament and wound-healing models rather than human treatment.
How it is described to act
- 1
In the published studies it is given by injection (subcutaneous or intraperitoneal) in animals, or orally in gut models; human pharmacokinetics are largely uncharacterised.
- 2
Animal studies report distribution to gastrointestinal and musculoskeletal tissue after dosing.
- 3
Authors propose interaction with growth-factor and nitric-oxide/VEGF-related angiogenic signalling; no specific receptor has been firmly established.
- 4
Observed effects come from rodent tendon-injury and gastric-ulcer models, plus one small uncontrolled human case series in knee pain.
What the research has looked at
Soft-tissue and tendon models
- In rodent models of tendon and ligament injury, researchers reported faster healing and better-organised collagen after BPC-157 administration (Cell and Tissue Research, 2019).
- The same review notes that these findings are from animal models and that human data are not available to confirm them.
Gastrointestinal models
- A 2025 literature and patent review in Pharmaceuticals summarised multiple animal studies reporting gastroprotective and anti-ulcer effects attributed to BPC-157.
- That review also states that no regulated clinical trial programme has established these effects in people.
Human data
- A 2021 case series in Alternative Therapies in Health and Medicine reported symptom improvement after intra-articular BPC-157 injection in patients with knee pain. A case series has no control group, so it cannot show cause and effect.
Strength of evidence: Preclinical evidence only
The overwhelming majority of published data are in rodents; the only human report located is a small uncontrolled case series, so efficacy and safety in people are unestablished.
What is published comes from cell and animal studies. Findings in those models frequently do not carry over to people.
Reported cautions and unknowns
- Because it has not been through a regulated clinical trial programme, no formal human safety or toxicology dataset exists (Pharmaceuticals, 2025).
- Reviewers flag that unregulated sourcing makes purity and actual content unverifiable, which confounds any reported outcome.
- Long-term effects, drug interactions, and — given the proposed angiogenic mechanism — any influence on existing tumours are described in the literature as unknown.
References
- 1.Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review, Pharmaceuticals (2025)
- 2.Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing, Cell and Tissue Research (2019)
- 3.Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain, Altern Ther Health Med (2021)
Handling this vial
- Reviews note that material sold online is unregulated, so neither the identity nor the purity of a given vial can be assumed without a current Certificate of Analysis.
- Lyophilized vials are generally stored at 2–8 °C and kept out of light; once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after 28 days.
- Mix by aiming water down the vial wall and rolling gently — do not shake — and never re-freeze a reconstituted vial.
- Pep-Tidy cannot verify what is in your vial. Ask your supplier for a current Certificate of Analysis (HPLC/MS).
BPC-157 questions people ask
How do you reconstitute BPC-157?
A common starting point for a 5 mg vial of BPC-157 is 2 mL of bacteriostatic water, which gives 2.5 mg per mL. Aim the water down the inside wall of the vial, let it dissolve on its own, and roll gently instead of shaking. Pep-Tidy's reconstitution calculator will recalculate the numbers for any other vial size or water volume you use.
How many units of BPC-157 is one dose?
At 2.5 mg per mL, that works out to about 10 units on a U-100 insulin syringe for a 250 mcg dose. Change the vial size, water volume, or target dose in the calculator and the syringe reading updates with it. This is arithmetic, not a dosing recommendation.
What dosing schedule is reported for BPC-157?
Published and community sources describe 200–500 mcg, subcutaneous, every day, typically run 4 weeks on and 2 weeks off. These figures describe what has been reported, not what anyone should take — talk to a licensed clinician first.
How should BPC-157 be stored?
Lyophilized BPC-157 vials are generally kept at 2–8 °C and out of light. Once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after about 28 days. Never re-freeze a reconstituted vial and never shake it.
Read this before you act on anything above
Everything on this page is a summary of what other people have published — it is not medical advice, not a recommendation, and not a dosing instruction. Reported dose ranges describe what appears in the literature or in community protocols, not what anyone should take. Talk to a licensed clinician before using any peptide.